Mohd Malik, MD
Psychiatry · Saint Louis, MONPI 1942208715
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $753,302 of the $955,943 with a category attached, or 78.8%. 35 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.3% of the total. Reporting peaked in 2019 at $288,356 and has fallen 99.6% since, to $1,017 in 2025. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,982 payments — averaging $482.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$232K
- Alkermes, Inc.$151K
- Otsuka America Pharmaceutical, Inc.$150K
- Johnson & Johnson$102K
- AbbVie$93K
- Teva Pharmaceuticals USA, Inc.$84K
- plus $143K from 29 others
Across 773 payments — averaging $2836.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$741K
- Teva Pharmaceuticals USA, Inc.$323K
- Hoffmann-la Roche Limited$216K
- Alkermes, Inc.$197K
- Orexo US, Inc.$174K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$144K
- plus $397K from 13 others
What the payments were for
- Consulting fees$59,0176%
- Speaking & faculty fees$753,30279%
- Travel & lodging$102,12011%
- Food & beverage$41,2144%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$424,333
- CAPLYTA$227,903
- LYBALVI$180,388
- ARISTADA INITIO$94,359
- VRAYLAR$89,884
- REXULTI$84,687
- LATUDA$69,110
- ABILIFY MAINTENA$65,515
- INVEGA SUSTENNA$62,131
- INVEGA TRINZA$51,000
- AUSTEDO$49,995
- Auvelity$37,893
- SPRAVATO$36,142
- Austedo XR$24,229
- INGREZZA$19,629
- ABILIFY ASIMTUFII$13,232
- UZEDY$6,660
- Zubsolv$2,505
- INVEGA$1,765
- VNS Therapy$1,012
How this compares
$955,943 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 135 | $264,721 |
| IngrezzaValbenazine Tosylate | 18 | $153,807 |
| Abilify MaintenaAripiprazole | 47 | $124,681 |
| AuvelityDextromethorphan Hbr/Bupropion | 44 | $61,819 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $55,103 |
| Invega SustennaPaliperidone Palmitate | 19 | $52,597 |
| SpravatoEsketamine Hcl | 38 | $35,600 |
| VraylarCariprazine Hcl | 21 | $32,530 |
| TrintellixVortioxetine Hydrobromide | 50 | $32,244 |
| RexultiBrexpiprazole | 14 | $22,575 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 124 | $18,604 |
| Risperidone ErRisperidone Microspheres | 14 | $14,773 |
| Lurasidone Hcl | 107 | $14,751 |
| QelbreeViloxazine Hcl | 13 | $11,524 |
| Clomipramine Hcl | 47 | $11,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $232,410 | $264,721135 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $20,906 | $153,80718 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $150,160 | $147,25661 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $102,434 | $88,19757 claims |
| Axsome Therapeutics, Inc.Auvelity | $38,321 | $61,81944 claims |
| Alkermes, Inc.Lybalvi | $151,216 | $55,10330 claims |
| AbbVieVraylar | $92,541 | $32,53021 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $467 | $32,24450 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $263 | $11,52413 claims |
| Indivior Inc.Suboxone | $308 | $8,67313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
- Eric LenzeSaint Louis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.